Published in

Springer, Clinical and Translational Oncology, 7(10), p. 426-432, 2008

DOI: 10.1007/s12094-008-0226-5

Links

Tools

Export citation

Search in Google Scholar

Impact of erythropoietin on the reduction of blood transfusions and on survival of lung cancer patients receiving first-line chemotherapy.

Journal article published in 2008 by Paula J. Fonseca, Emilio Esteban, Pilar de Vicente, Miguel Luque, Bertrand Llorente, Marta Capelan, José Pablo Berros, Guillermo Crespo ORCID, Ángel Jiménez Lacave
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Anaemia is a common problem in patients with cancer who receive chemotherapy and is normally associated with a negative impact on patients' quality of life (QOL), poor cancer control and diminished survival. In clinical trials, recombinant human erythropoietin has been shown to correct and prevent anaemia, decrease the need for blood transfusions and improve cancer patients' QOL. ; Historical Article ; Journal Article ; info:eu-repo/semantics/published